Compositions and methods for treating cocaine-related disorders
Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
1. A method for treating a cocaine-related disorder in an individual, comprising administering to the individual a therapeutic amount of a monoclonal antibody comprising a human gamma heavy chain and a murine lambda light chain, wherein the antibody specifically binds cocaine and is generated by immunizing a HCo7/Ko5 mouse with an antigen comprising a conjugate of benzoylecgonine and an immunogenic carrier protein, wherein the murine lambda light chain comprises SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 and wherein the human gamma heavy chain comprises SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, wherein the antibody binds cocaine or a derivative thereof.
2. The method of claim 1 , wherein the murine lambda light chain comprises a murine variable region and a human constant region.
3. The method of claim 1 , wherein the murine lambda light chain comprises SEQ ID NO: 1.
4. The method of claim 1 , wherein the antibody has at least a nanomolar affinity for cocaine.
5. The method of claim 1 , wherein the antibody has a K d of about 40 nM or less.
6. The method of claim 5 , wherein the antibody has a K d of about 4 nM.
7. The method of claim 1 , wherein the cocaine-related disorder comprises at least one of overdose, addiction, dependence, and relapse.
8. The method of claim 1 , wherein the human gamma heavy chain comprises SEQ ID NO: 2.
9. The method of claim 8 , wherein the murine lambda light chain comprises SEQ ID NO: 1.
10. The method of claim 1 , wherein the murine lambda light chain comprises a murine variable region and a murine constant region.
11. A monoclonal antibody comprising a human gamma heavy chain and a murine lambda light chain, wherein the antibody specifically binds cocaine and is generated by immunizing a HCo7/Ko5 mouse with an antigen comprising a conjugate of benzoylecgonine and an immunogenic carrier protein, wherein the murine lambda light chain comprises SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 and wherein the human gamma heavy chain comprises SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
12. The monoclonal antibody of claim 11 , wherein the murine lambda light chain comprises SEQ ID NO: 1.
13. The monoclonal antibody of claim 11 , wherein the human gamma heavy chain comprises SEQ ID NO: 2.
14. The monoclonal antibody of claim 11 , wherein the murine lambda light chain comprises a murine variable region and a murine constant region.
15. The monoclonal antibody of claim 11 , wherein the murine lambda light chain comprises a murine variable region and a human constant region.
16. A method for binding cocaine or a derivative thereof comprising contacting cocaine or a derivative thereof with an effective amount of a monoclonal antibody comprising a human gamma heavy chain and a murine lambda light chain, wherein the antibody specifically binds cocaine and is generated by immunizing a HCo7/Ko5 mouse with an antigen comprising a conjugate of benzoylecgonine and an immunogenic carrier protein, wherein the murine lambda light chain comprises SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 and wherein the human gamma heavy chain comprises SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.